Drugmaker Valeant close to buying Salix – source
By Nadia Damouni NEW YORK (Reuters) – Valeant Pharmaceuticals International Inc is close to a $ 10.2 billion deal to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd, according to a person directly familiar with the matter. The agreement with Salix, known for its irritable bowel syndrome drug Xifaxan, for around $ 160 per share could come as early as next week, the source said on Friday, requesting not to be identified as the matter is confidential. Salix's stock jumped 4.1 percent to $ 156.97 in afternoon trading on the Nasdaq. A deal of that size would be the largest ever for Valeant, which lost a takeover contest for Allergan Inc last year.
More From Around the Web
Check out these Articles
- Did reports of side effects contribute to drop in bone drug use?
- Stada first-quarter profit beats on German generic boost
- FDA warns India’s Sun Pharma for violating manufacturing standards
- Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion: ...
- Death penalty repeal bill advances in Nebraska legislature
- FedEx faces U.S. criminal charges over online pharmacies
- Glowing terms often used for new cancer drugs in health news
- Action needed as decline in HIV cases stalls, AIDS agency says
- Baby boomers often unaware they need hepatitis C screening
- CVS posts slightly higher-than-expected quarterly results
- Heron drug for post-surgery pain succeeds in midstage trial
- Hepatitis C linked to higher risk of head and neck cancers
- Teva’s MS drug Copaxone has strong second-quarter sales